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Abstract
Members of the P2X family of ligand-gated cation channels (P2RX) are expressed by various cell types including neurons,
smooth- and cardiac muscle cells, and leukocytes. The channels mediate signalling in response to extracellular ATP. Seven
subunit isoforms (P2RX1-P2RX7) have been identified and these can assemble as homo- and heterotrimeric molecules. In
humans, P2RX5 exists as a natural deletion mutant lacking amino acids 328–349 of exon 10, which are part of
transmembrane (TM) 2 and pre-TM2 regions in other organisms like rat, chicken and zebrafish. We show that P2RX5 gene
expression of human T lymphocytes is upregulated during activation. P2RX5 is recruited to the cell surface. P2RX5-siRNA-
transfected CD4+ T cells produced twofold more IL-10 than controls. Surface and intracellular P2RX5 expression was
upregulated in activated antigen-specific CD4+ T cell clones. These data indicate a functional role of the human P2RX5 splice
variant in T cell activation and immunoregulation.
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Introduction
An intimate cell-cell contact between a T cell and an antigen-
presenting cell (APC) elicits T cell activation. It is associated with
immunological synapse (IS) formation at the T cell surface,
morphologically recognizable as a polarized structure, supramo-
lecular activation cluster (SMAC) [1–3]. Detailed immunological
studies have investigated and characterized the role of SMAC
proteins in the initiation process of IS formation [1,2]. Much less is
known about later phases of T cell activation, involving IS
organization and maintenance [4]. CD4+ T cell interactions with
APCs at the IS may last for 6 h or more [5,6]. IS-engagement
results in Ca2+-mediated signalling events which participate in
modulating T cell activation [7–9]. Depending on its timing and
composition IS formation may result in several outcomes including
anergy induction, full activation, activation-induced cell death,
and these are involved in tight control of T cell activation under
physiological and autoimmune conditions [10–13].
To mount an efficient immune response activated T cells
require a sustained increase in intracellular Ca2+ concentration
[Ca2+]i preceded by elevated Ca
2+-ion influx [14–17]. This
involves upregulation of ion channels, such as the Ca2+ release-
activated Ca2+ channel (CRAC) and the Ca2+-activated potassium
intermediate/small conductance calcium-activated channel, sub-
family N, member 4 (KCNN4) K+ channel, which accumulate
within the IS at the cell surface of the activated T cell [18,19]. As
an early step of the activation process ion channel mRNA
expression is upregulated resulting in increased ion channel
density at the cell surface. Here, we wanted to address if T cell
activation involves upregulation of additional ion channel activities
to effectively regulate [Ca2+]i homeostasis and to clamp elevated
[Ca2+]i for longer durations. Therefore, we activated primary
human CD4+ T cells and systematically characterized changes in
expression levels of ion channel mRNAs by using oligonucleotide-
based arrays. In addition to CRAC and KCNN4 channel
subunits, T cell activation affected expression levels of only a
few other ion channel mRNAs. The most prominent mRNA
upregulation, however, was observed for purinergic receptor P2X,
ligand-gated ion channel, 5 (P2RX5), a member of the purinergic
receptor gene family 2 with unknown function in humans [20]. We
show that P2RX5 accumulates at the surface of activated CD4+ T
cells. Moreover, both intracellular and surface expression of
P2RX5 by human T cell clones (TCCs) were dependent on T cell
activation. P2RX5 mRNA knock-down experiments established
P2RX5 as a novel regulatory component of T cell polarity and
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implicate P2RX5 in the regulation of synaptic IL-10 secretion.
Hence, P2RX5 represents a functional surface membrane
component of activated T cells with an apparent role during the
later phase of T cell polarity and the secretion of the regulatory
cytokine IL-10.
Results
P2RX5 is upregulated during CD4+ T cell activation
In exploratory experiments we stimulated PBMCs with PHA-L
for 72 h to profile changes in mRNA expression of 188 subunits of
cell surface ion channels with a custom-made oligonucleotide-
based array (Table S1). Activation of primary human T cells
resulted in a $ twofold increase or decrease in mRNA expression
(Fig. 1A, B; Table S2) of only a few ion channel subunit genes
(upregulated: TRPV2, KCNAB2, KCNMA1, KCNN4, CLCN7,
CLNS1A, STIM1, Orai1; downregulated: KCNJ2, KCNMB1).
This compares with a twenty-six-fold increase in expression of
CD25 mRNA, a prototypic marker for T cell activation (Fig. 1B).
Subsequent analysis using a genome-wide expression array, which
extends the above experiment to ion channel subunits targeted to
intracellular compartments (Fig. 1B), indicated a comparably
small number of ion channel subunit genes that displayed a $
two-fold increase or decrease in expression upon PHA-L
stimulation (Fig. 1). Consistent with our hypothesis, PHA-L
activation of PBMCs upregulated a distinct mRNA set for ion
channels, e.g. IP3 receptors, Ca
2+-regulated Ca2+-, Ca2+-activated
K+-, and Cl- (anion)-channels. Recent data on transient receptor
potential (TRP) expression in activated primary human T cells
describe increased expression of TRPM2 96 h after activation
with anti-CD3/anti-CD28 antibody-coated beads [21]. Notably,
the additionally found TRPC3 upregulation, which shows
different kinetics compared to TRPM2, was not identified by
our genome-wide expression array.
We then quantified mRNA expression of specific cell surface ion
channels in activated T cells. We stimulated purifed CD4+ and
CD8+ T cells with PHA-L or with soluble anti-CD3 before
separating the T cells for qPCR analysis (Fig. S1A, B).
Subsequently, we analyzed mRNA expression of purified CD4+
or CD8+ T cells separately following activation with anti-CD3/
anti-CD28 antibody-coated beads (Fig. 1C). The different stimu-
lation protocols yielded qualitatively similar results. In comparison
to the array data, the qPCR data, however, exhibited markedly
larger changes in mRNA expression (Fig. 1C; Fig. S1A, B), in
particular for the expression of KCNN4 and P2RX5 mRNA in
CD4+ T cells (Fig. 1C). The , thirteen-fold increase in the level of
P2RX5 mRNA in activated CD4+ T cells (13.061.2; n = 3) stood
out against data of the other ion channel subunit mRNAs.
Therefore, we concentrated in our further investigations on
P2RX5, which is highly expressed in lymphoid tissue [22].
The exponential time course of P2RX5 mRNA upregulation in
stimulated CD4+ T cells (Fig. 1D) was well described with one
time constant (t= 19.5 hr). In comparison, CD25 mRNA
upregulation, which occurs early in T cell activation [15], is
significantly faster (t= 7.4 hr) and quite insensitive to cyclohexi-
mide, a protein synthesis inhibitor (Fig. S1C). By contrast,
stimulation of P2RX5 mRNA expression was highly sensitive to
cycloheximide (Fig. 1D). Using a monoclonal antibody raised
against aa 126 to 224, Western blot analysis of P2RX5 expression
showed that activated CD4+ T cells express significantly more
protein than resting CD4+ T cells (Fig. 2A). Importantly, HEK293
cells transfected with truncated P2RX5 cDNA show a distinct
signal at 55–60 kDa which correlates with the T cell-derived
signal. A comparably weak signal can be detected at 45–50 kDa
which corresponds to unmodified truncated P2RX5 protein. The
increase in P2RX5 protein expression matches the observed
increase in P2RX5 mRNA expression.
P2RX5 is recruited to the surface of activated CD4+ T cells
Next, we investigated the membrane localization of P2RX5 in
soluble anti-CD3 antibody-activated CD4+ T cells. Using sulfo-
NHS-SS-biotin to biotinylate cell surface proteins, we separated
biotinylated and non-biotinylated protein for Western blot analysis
(Fig. 2). We used CD3e and GAPDH as a marker for cell surface
and cytoplasmic protein, respectively. Controls showed that
P2RX5 protein appeared in lysates of resting CD4+ T cells
exclusively in the non-biotinylated protein fraction (UB- in
Fig. 2B). In lysates of activated CD4+ T cells, however, we
detected P2RX5 in both the biotinylated and the non-biotinylated
protein fractions (Fig. 2B). Clearly, P2RX5 protein is able to
localize to the cell surface of activated human CD4+ T cells.
In agreement with the biochemical data, immunofluorescent
staining experiments using polyclonal anti-P2RX5 antibody
showed that resting CD4+ T cells display a homogeneous
distribution of P2RX5 protein at and below the cell surface
(Fig. 3A). In activated CD4+ T cells, by contrast, P2RX5 protein
exhibited a more polar distribution (Fig. 3B). Double-image
immunofluorescence analysis of activated CD4+ T cells demon-
strated that talin, a typical SMAC protein, and P2RX5 colocalize
both in resting and in activated CD4+ T cells (Fig. 3C, D; Fig.
S1D). The results suggest that P2RX5 is not only recruited to the
membrane of activated T cells, but it may also be involved in T
cell polarity upon activation.
P2RX5 plays a role in sustaining CD4+ T cell polarity
SMAC proteins are involved in IS establishment, organization,
and maintenance [3]. Based on the above data we reasoned that
P2RX5 participates in later stages of SMAC formation and/or
maintenance as well as subsequent steps following T cell
activation. This hypothesis was addressed in knock-down exper-
iments. CD4+ T cells were transfected with siRNA directed against
P2RX5 mRNA (P2RX5-siRNA) in order to interfere with P2RX5
expression. Scrambled siRNA served as control (control-siRNA).
The transfection efficiency was ,50 to 60% based on experiments
with eGFP cDNA (data not shown). Western blot analysis of
activated, P2RX5-siRNA-transfected CD4+ T cells indicated an
approximately 50% reduction in P2RX5 protein expression
(Fig. 4A). Next, we investigated the effect of siRNA transfection
on CD4+ T cell polarity with talin as SMAC marker. 4 h after
activation, we observed no significant difference in the polar
distribution of talin between P2RX5-siRNA-transfected CD4+ T
cells and controls (Fig. 4B), indicating that P2RX5 is not involved
in the initial establishment of CD4+ T cell polarity. In contrast,
24 h after activation, P2RX5-siRNA-transfected CD4+-cells
exhibited a significant loss of polarized talin distribution concom-
itant with a markedly reduced intensity of talin immunostain
(Fig. 4C). Quantitative analysis of the immunostaining patterns
(Fig. 4D) showed approximately half as many CD4+ T cells with a
polarized talin distribution in P2RX5-siRNA- versus in control-
siRNA-transfected cells (Fig. 4D). We obtained very similar data,
when we immunostained siRNA-transfected and activated CD4+
T cells with anti-LFA-1 antibodies (Fig. 4D). Our results
emphasize the involvement of P2RX5 in sustained polar SMAC
protein distribution in activated CD4+ T cells.
P2RX5 modulates IL-10 production of CD4+ T cells
The effect of P2RX5 on CD4+ T cell polarity resembled that of
class-I MHC-restricted T cell-associated molecule (Crtam), a
Role of P2RX5 Variant in T Cell Polarity
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transmembrane protein of the Ig superfamily. Importantly, Crtam
enables activated CD4+Crtam+ T cells to selectively produce more
IFN-c and IL-22 [4]. The comparison of P2RX5 and Crtam
properties suggested that P2RX5 might also modulate the cytokine
production of activated CD4+ T cells. Thus, we assessed the
production of IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, and IL-
12p70, IFN-c, TNF-a, and TNF-b assaying non-transfected-,
P2RX5-siRNA-transfected, and control-siRNA-transfected CD4+
T cells, respectively. CD4+ T cells activated with anti-CD3/CD28
antibody-coated beads mainly produced IL-2 (Fig. S1E). In
addition, we detected significant amounts of IL-10, IFN-c, and
TNF-a (Fig. 4E, F). Concentrations of other interleukins were very
low or below the detection limit (Fig. S1E). Interestingly, we
observed that activated P2RX5-siRNA-transfected CD4+ T cells
produced significantly more IL-10 than controls, although the
knock-down was incomplete (Fig. 4E). Production of all other
interleukins that we tested was unaffected by the P2RX5 knock-
down. Taken together, our data indicate that P2RX5 among the
examined cytokines selectively modulates the production of IL-10
at a later phase of CD4+ T cell activation.
The comparison of P2RX5 and Crtam showed another
interesting difference. Crtam2 T cells are hyper-proliferative in
comparison to controls. In contrast, knock-down of P2RX5 leads
to a reduction in T cell number. In comparison to controls, we
Figure 1. T cell activation alters mRNA expression of specific ion channel subunits. A, B, Bar diagram summarizing n-fold increase or
decrease in intensity of hybridization signals obtained by probing oligonucleotide-based arrays with Cy3 and Cy5 labeled cDNA derived from mRNA
isolated from non-activated and PHA-L activated PBMCs, respectively. Gray bars – custom-made array (n = 14) (Tables S1, S2); black bars – Affimetrix
array (human U133A 2.0; n = 6). Error bars are SEM. Channel subunit genes are indicated on the left. Nomenclature is from http://www.ncbi.nlm.nih.
gov/omim. Brackets - selectivity of corresponding ion channel. cat – cation; n.p. – not present in array; n.d. – not determined. CD25 (IL2RA) served as
control. C, Bar diagram summarizing qPCR results for changes in mRNA expression of purified CD4+ and CD8+ T cells activated with anti-CD3/CD28
antibody-coated beads (n = 5–8). D, qPCR analysis of P2RX5 mRNA expression in activated CD4+ T cells in absence (m) or presence (%) of
cycloheximide (n = 3). Error bars are SEM.
doi:10.1371/journal.pone.0104692.g001
Figure 2. CD4+ T cell activation increases P2RX5 protein
expression. A, Western blot of non-activated (CD4+/2) and activated
(CD4+/+) CD4+ T cell lysates and of P2RX5 cDNA transfected (HEK293/+)
or mock-transfected (HEK293/m) HEK293 cell lysates. Blots were stained
with anti-P2RX5 antibody. Staining with anti-GAPDH antibody (arrow)
served as loading control. B, Western blot of protein biotinylated at the
cell surface of activated CD4+ T cells (+) and of controls (2). Protein was
fractionated with streptavidin-agarose. B – streptavidin-agarose bound
fraction; UB – unbound protein fraction. Western blots were stained
with antibodies against P2RX5, GAPDH, and CD3e as indicated by
arrows.
doi:10.1371/journal.pone.0104692.g002
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noted a significant reduction (,60%) in the number of activated
CD4+ T cells after transfection with P2RX5-siRNA (Fig. S1F).
P2RX5 expression in T cell subsets
We analyzed the surface P2RX5 expression in bulk CD4+ and
CD8+ T cells as well as their respective CD45RA+CD27+ naı¨ve
and CD45RA-CD27+ memory subsets (Fig. S1G, H). Our data
indicate that only a fraction of resting CD4+ and CD8+ T cells
expresses P2RX5, and that this fraction is almost three times
higher in CD8+ T cells. Furthermore, in both T cell compartments
P2RX5 expression is higher in the resting naı¨ve population albeit
only slightly in CD4+ and clearly more pronounced in naı¨ve CD8+
T cells.
CD4+ T cell clones upregulate expression of P2RX5 in
response to stimulation
The above described differences of P2RX5 expression in CD4+
versus CD8+ T cells and their differentiation stages rendered
interpretation of the dynamics difficult, and therefore we next
examined the expression of P2RX5 in well-defined antigen-
specific CD4+ TCCs [23]. We utilized two IFN-c-secreting Th1
TCCs designated 3A and 11B, one IFN-c and IL-17 double-
producing TCC 25 as well as one TCC 12B, which produced IFN-
c but also IL-4 representing a Th1-2 phenotype (Table S3).
Regardless of the phenotype we found a strong increase in
frequencies of P2RX5+ cells in cell surface staining experiments if
TCCs were stimulated (Fig. 5A). Moreover, also in the case of
intracellular stainings the P2RX5+ populations of TCCs were
markedly increased upon stimulation (data not shown). This highly
dynamic, increased frequency of cells expressing P2RX5 was also
accompanied by an increase of P2RX5 expression levels on the
cell surface (Fig. 5B). As a control, we cultured HEK293 cells with
or without beads coated with antibodies against CD2, CD3 and
CD28. After 24 h we subjected these cells to surface as well as
intracellular staining for P2RX5. Regardless of the culture
conditions HEK293 cells were found to be positive for P2RX5.
When focusing on expression levels, only a limited number of
P2RX5 was found to be located on the cell surface of HEK293
cells (medFI = 2,460, Fig. 5C) whereas these cells contained high
intracellular amounts of P2RX5 (medFI = 42,377) consistent with
published data [24]. In contrast to HEK293 cells, P2RX5
expression by TCCs appeared to be induced upon activation.
The strong intracellular, but also cell surface upregulation resulted
in significantly elevated frequencies of P2RX5+ TCCs (Fig. 5D).
The data illustrate the tight regulation of P2RX5 expression by
activation in T cells.
TCCs express a spliced variant of P2RX5
Th1 TCC 18B as well as TCC 14A showing a Th1-2 phenotype
were used to address if P2RX5 expressed by T cells is the full-
length molecule or the previously described truncation variant.
mRNA was isolated and PCR-amplified after 24 h of cell culture
with or without activation by anti-CD3. Sequencing revealed that
human TCCs expressed a splice variant, which lacks exon 10
comprising 66 nucleotides (Fig. 5E). These results confirmed our
previous findings, which were generated by culture of enriched
CD4+ T cells with or without the addition of anti-CD3 (data not
shown). Thus, human T cells do not express the full-length
P2RX5, which functions as an ion channel.
Discussion
Our work reveals a novel P2RX5 function in human immune
cell activation. Full length P2RX5 expresses an established
purinergic cation channel [25–29]. Here we show a link between
the activation of human T cells and the expression of a P2RX5
variant, which contains an internal deletion disabling P2RX5
channel function [24,30]. The truncated P2RX5 isoform serves as
an ‘‘activation marker’’ molecule of T cells upon stimulation.
Furthermore, it acts as a modulator of IL-10 production.
Starting from a systematic analysis of ion channel genes that are
expressed upon T cell activation, we observed the most prominent
increase for P2RX5 mRNA and therefore focused on this
molecule. Subsequent studies of its expression time-course and
cycloheximide sensitivity in activated CD4+ T cells argue against
an important role of P2RX5 protein in the initial phase of CD4+ T
cell activation. The observed increase in P2RX5 mRNA and
protein concentration is likely a secondary or delayed response and
suggests a functional role of P2RX5 in a later phase of CD4+ T cell
activation.
Human CD4+ T cells express a P2RX5 variant (P2RX5D)
lacking part of the second membrane-spanning segment that is
essential for formation of the conduction pathway and P2R-ion
channel activity [24,30]. It is unlikely that lymphoid P2RX5D
protein participates in P2R-like cation channel assembly [20,24].
Previous heterologous expression studies in tissue culture cells even
suggested that P2RX5D does not migrate to the cell surface [24].
Here, we show that P2RX5D protein is able to localize to the cell
surface of activated human CD4+ T cells. The polar distribution of
P2RX5D resembles that of CRAC and KCNN4 channels, which
accumulate shortly after activation within an IS-associated SMAC
[19]. Indeed, colocalization with talin suggests that P2RX5D
represents a novel SMAC protein component.
The trimeric architecture of functional P2RX5 channels
depends on the presence of Asp355 within transmembrane 2
(TM2) region of P2RX5 [24]. The deletion of a significant part of
TM2 in P2RX5D most likely obviates P2RX5 trimerization into
functional channels [30]. Due to the TM2 deletion, P2RX5D may
Figure 3. P2RX5 protein is redistributed upon T cell stimula-
tion. T cells were incubated with either streptavidin beads for control
(A, C) or anti-CD3/CD28 antibody-coated streptavidin beads (B, D) for
activation. A, B, immunostaining pattern obtained with anti-P2RX5
antibodies (green). C, D, overlayed double fluorescence images
obtained with anti-talin (green) and with anti-P2RX5 antibodies (red),
pictures represent magnifications of overviews depicted in Fig. S1D.
Scale bars – 10 mm.
doi:10.1371/journal.pone.0104692.g003
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adopt a membrane topology with only one transmembrane
spanning segment (TM1) and a carboxy-terminus pointing
towards the extracellular space, if P2RX5D is transported to the
cell surface, like in activated CD4+ cells. Important to note,
P2RX5D, when overexpressed in in vitro expression systems, has
the tendency to aggregate [24]. An attractive hypothesis is that
P2RX5D aggregate formation at the cell surface may play a role in
homotypic or heterotypic immune cell interactions. This proposed
function of P2RX5D in activated T cells awaits further investiga-
tion, possibly by the use of monoclonal antibodies specific for
intracellular, transmembrane or extracellular domains of P2RX5
once these become available. Also, the SMAC localization of
P2XR5 may indirectly influence CRAC channel activity and Ca2+
mobilization in lymphocytes, which should be investigated in the
future.
By performing knock-down experiments of P2RX5 in activated
CD4+ T cells we showed that P2RX5D affects the polar
distribution of SMAC proteins talin and LFA-1 during a later
phase of CD4+ T cell activation (between .4 h and ,24 h). The
consequence of P2RX5D expression on T cell polarity indicates
mechanistic similarities with Crtam. Crtam is essential for
sustaining CD4+ T cell polarity at a later phase of T cell activation
in a subset of CD4+ T cells (CD4+Crtam+ T cells). Crtam is not
expressed on the surface of resting naı¨ve CD4+CD62L+ T cells,
but is upregulated on CD4+ T cell subsets 14 h after activation
followed by down-modulation within 24 h, thereby modulating
IFN-c production [4]. Remarkably, our results also indicate a role
for P2RX5D in the modulation of interleukin production by
activated CD4+ T cells. Partial knock-down of P2RX5D resulted
in a significant increase in IL-10 production upon T cell
activation. The data indicates that P2RX5D and Crtam regulate
the production of different cytokines. Possibly, P2RX5D and
Crtam are active in different subsets of CD4+ T cells or
alternatively in the case of P2RX5D the relative expression level
influences cytokine secretion and subsequently functional out-
comes of T cell/APC interaction. Since none of the available
commercial anti-P2RX5 antibodies specifically recognized an
external P2RX5D epitope, we were unable to test this hypothesis
directly in respective cell sorting experiments.
IL-10 is a potent immunoregulatory and anti-inflammatory
cytokine that may directly or indirectly inhibit T cell proliferation
[31,32]. Notably, organ-specific IL-10 production has been
identified to evoke autoimmunity in a mouse model of diabetes
[33]. In this context it is noteworthy that a recent report identified
hematopoietic-restricted minor histocompatibility antigen, LRH-
1, as a P2RX5 splice variant with an altered C-terminal sequence.
Aberrant expression of this splice variant leads to cytotoxic T cell-
mediated cell lysis [34]. Also, a truncated P2RX5 protein resulting
from a premature stop codon in the third exon of P2RX5 has been
implicated in certain lymphoid malignancies [22]. It will be
interesting to investigate if alterations of T cell activation and IL-
10 production occur in these malignancies.
Figure 4. P2RX5 knock-down affects CD4+ T cell polarity and IL-10 secretion. A, Western blot analysis of P2RX5, talin, and LFA-1 expression
in activated CD4+ T cells transfected with siRNA as indicated. GAPDH served as loading control. B, C, CD4+ T cells were transfected with indicated
siRNA followed by activation for 4 or 24 h. Cells were stained with anti-talin antibodies. Scale bar – 10 mm. D, Bar diagram illustrating relative number
of polarized CD4+ T cells seen with talin or LFA-1 immunostains. E, Bar diagram illustrating interleukin production of activated non-transfected (grey
bars), control siRNA (white bars) or P2RX5-siRNA transfected (black bars) CD4+ T cells (n = 3 donors). Error bars are SEM, n.s. – non significant; * - p,
0.05, ** p,0.01 (Student’s T-test).
doi:10.1371/journal.pone.0104692.g004
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With respect to P2RX5+ fractions within CD4+ and CD8+ T
cells we can only speculate about the possible causes at the
moment. The higher frequency of P2RX5-expressing naı¨ve versus
P2RX5+ T cells in both compartments could indicate that
P2RX5+ naı¨ve cells recently received a stimulus, e.g. TCR-
HLA/self-peptide interactions, which are the main signal for
homeostatic proliferation. Interactions between costimulatory
molecules such as CD80 or CD86 on APCs and their ligands
(CD28/CTLA-4) influence the level of T cell activation [35–37].
Different costimulatory requirements of CD4+ and CD8+ T cell
responses point to distinct mechanisms to activate these cells [38–
40], and P2RX5 may be an additional factor involved in
modulating T cell activation, however, dissecting the expression
of P2RX5 in subsets of T cells, its role in their activation and
possible effects on functional differentiation all need to be studied
in the future.
Mechanistic changes of P2RX5D expression upon stimulation
became even more evident in fully differentiated, clonal T cell
populations. T cell activation increased the fraction of P2RX5+
cells within a TCC with respect to both surface and intracellular
stainings as well as the level of surface P2RX5D expression in
comparison to resting TCCs. Thus, the data obtained with
antigen-specific TCCs confirmed the indicative expression pat-
terns of P2RX5D in bulk populations as a function of activation of
a T cell.
In summary our data demonstrate a role of P2RX5D, a
truncated isoform of the P2RX5 ion channel in the late stage of T
cell activation. They provide the basis for further studies of the role
of this molecule in physiological and pathological conditions.
Materials and Methods
Ethics Statement
The protocol, under which the studies were pursued, was
approved by the responsible local IRB, i.e. the Ethik Kommission
der A¨rztekammer Hamburg (Number of approved protocol:
2758). All participants signed a written informed consent prior
to donating any samples, and the consent documents were part of
the abovementioned, approved protocol. Consent documents are
kept on file as part of the conduct of studies with human samples
according to international standards and as stipulated by the
responsible IRB.
Cell Culture
PBMCs were isolated through a Ficoll (Biochrom, Berlin,
Germany) density gradient centrifugation (400xg, 40 min, RT).
PBMCs were resuspended in MACS buffer (0.5% BSA, 2.0 mM
EDTA in PBS). PBMC activation was initiated by adding PHA-L
(Sigma-Aldrich, St. Louis, MO, USA) to a final concentration of
31 nM for 72 h at 37uC. Where indicated, we activated by
addition of 10 mg anti-CD3 rabbit antibodies/ml (DOKA,
Glostrup, Denmark). CD4+ and CD8+ T cells were isolated by
negative selection using the CD4+/CD8+ T cell Isolation Kit II
(Miltenyi Biotec, Bergisch Gladbach, Germany) following the
manufacturer’s instructions. Purified T cells were resuspended in
RPMI 1640 medium supplemented with 10% FCS (PAA,
Pasching, Austria), 1% L-glutamine, 100 units/ml penicillin, and
0.1 mg/ml streptomycin (Invitrogen, Carlsbad, CA, USA). Purity
of isolated CD4+ and CD8+ T cells was 94–97%. Stimulation of
purified CD4+ and CD8+ T cells was performed in 96-well
Figure 5. Expression of P2RX5 by human T cells is highly dynamic and activation-dependent. A, Stimulation of human CD4+ TCCs
resulted in a significant increase in frequencies of cells expressing P2RX5 on the cell surface. B, Notably, surface expression levels were also
upregulated. C, P2RX5 expression was considerably lower on the surface of HEK293 cells. D, Summary of significantly increased frequencies of surface
P2RX5-expressing TCCs upon stimulation. Cell surface expression of P2RX5 was also upregulated on CD4+ TCCs. Bars represent mean values 6SEM.
Statistical analysis was performed by paired t-test, **p,0.01. E, Sequencing of two CD4+ TCCs cultivated under stimulated (+) or unstimulated (2)
conditions revealed that human Th1 and Th1/2 cells were expressing a transcript variant of P2RX5 lacking exon 10.
doi:10.1371/journal.pone.0104692.g005
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microtiter plates (Microtest Tissue Culture Plates, Falcon, BD
Biosciences, Franklin Lakes, NJ, USA). Each well contained 26105
cells in 200 mL X-Vivo 15-medium (Lonza, Basel, Switzerland), to
which 56104 anti-CD3/CD28 monoclonal antibody-coated beads
(Invitrogen) were added. Unless indicated otherwise, incubation
times were 72 h at 37uC. Experiments in the presence of
cycloheximide were done adding 50 ng/ml to the medium for
the times indicated.
Microarray procedures
Total RNA was isolated from 16107 cells using TRIzol
(Invitrogen). Fluorescent cDNA probes for stimulated and
unstimulated samples were prepared by reverse transcription of
mRNAs with aminoallyl-dUTP followed by Cy3 and Cy5 labelling
according to the manufacturer’s protocol (Amersham Pharmacia
Biotech, Uppsala, Sweden). Labeled cDNAs were hybridized to
oligonucleotide-based custom-made array. Array composition and
evaluation is given in Tables S1, S2. Hybridization chambers were
from Monterey Industries, Richmond, CA, USA. Blocking
hybridization and staining was as described [41,42]. Hybridization
signals were scanned with ‘arrayWORX’ scanner (Applied
Precision, Issaquah, WA, USA). Fluorescent images of hybridized
microarrays were analyzed with ScanAlyze software (http://rana.
lbl.gov/EisenSoftware.htm). Fluorescence ratios were stored in a
custom data base, and normalized data were extracted from this
data base for further analysis with Array Assist software
(Stratagene, La Jolla, CA, USA). Array data were filtered by
selecting signals that were present on at least 75% of the arrays,
had a spot diameter of $25 mm and a signal intensity of $200 in
each channel. For normalization of hybridization signals, we
added externally defined amounts of cDNA of three Zea maize
genes (aeI, DD1B, CE11). Probes for a-IL-2 receptor (IL2RA or
CD25) served as positive control for increased mRNA expression
in activated PBMCs [43].
Affymetrix (Santa Clara, CA, USA) protocols were used for
hybridization with labeled cDNA, washing and scanning of
Affymetrix U133A 2.0 human genome arrays. Scanned micro-
array images were analyzed with Affymetrix Analysis Suite
software with default analysis parameters. Data were then
exported for querying and annotation (GDS785). Microarray
data is available at www.ncbi.nlm.nih.gov/geo/ (GEO accession:
GSE22387, GSE21837).
Real-time quantitative polymerase chain reactions
RNA, extracted from PHA-L or anti-CD3 antibody (clone
OKT3)-activated T cells with TRIzol reagent, was reverse
transcribed with SuperScript First-Strand Synthesis system for
RT-PCR (Invitrogen). For quantitative PCR (qPCR) we used
prefabricated Taqman assays and a 7900 HT Sequence Detection
System instrument (Applied Biosystems, Foster City, CA, USA).
Data were normalized to CD247 gene expression to calculate n-
fold expression changes.
Transfection of HEK293 cells
HEK293 cells were transfected with P2RX5-pcDNA3 and
lipofectamin following the manufacturer’s protocol (Qiagen,
Hilden, Germany). For control we transfected HEK293 cells with
empty pcDNA3 vector.
Biotinylation of cell surface protein
Soluble anti-CD3 antibody-activated CD4+ T cells were labeled
with 10 mM sulfo-NHS-SS-biotin. Biotinylated cell surface
proteins were separated from non-biotinylated intracellular
proteins using the cell surface protein isolation kit (Pierce,
Rockford, IL, USA). Collected fractions of bound and unbound
protein were immunoblotted for analysis.
Immunoblotting and immunocytochemistry
CD4+ T cells resuspended in 1% protein inhibitor mix (Sigma-
Aldrich) were lysed by repeated freezing in liquid nitrogen and
thawing. After adding 206 PBS lysates were spun at 2000xg for
3 min. The supernatant was centrifuged at 18,000xg for 20 min.
The pellet was taken up in 100 mM NaCl, 50 mM HEPES
(pH 7.4), 1% protein inhibitor mix, and 0.5% Triton-X-100 (Carl
Roth, Karlsruhe, Germany). Proteins were separated on 10%
NuPAGE Bis-Tris gels (Invitrogen) and blotted onto nitrocellulose
membranes (Mini-Transblot, Bio-Rad, Munich, Germany) for
immunodetection. Primary antibodies were anti-P2RX5 (clone
1C5 for immunoblotting or polyclonal for immunocytochemistry,
Abnova, Taipei, Taiwan), anti-talin (clone 8d4, Sigma-Aldrich),
anti-GAPDH (clone GAPDH-71.1, Sigma-Aldrich) monoclonal
mouse antibodies, and anti-LFA-1 (against integrin, alpha-L, clone
EP1285Y, Abcam, Cambridge, UK) monoclonal rabbit antibody.
Secondary antibodies were anti-mouse HRP-coupled polyclonal
sheep IgGs (Jackson ImmunoResearch, Newmarket, UK) and
anti-rabbit HRP-coupled polyclonal IgGs (Jackson ImmunoRe-
search). CD4+ T cells were fixed and immunostained essentially as
described [44]. Secondary Alexa488- and Alexa546-conjugated
antibodies were from Invitrogen. Fluorescence images were taken
with a Fluoview Fv1000 confocal microscope (Olympus, Tokio,
Japan).
siRNA transfection experiments
CD4+ T cells were transfected with P2RX5- and control-siRNA
(Dharmacon, Lafayette, CO, USA, lot No. L-006286-00-0005
and, respectively, L-001810-10-05) using the Human T Cell
Nucleofector Kit (Amaxa, Germany). Transfection efficiency was
assessed under an inverted fluorescence microscope by counting
cells with eGFP fluorescence versus total cell number. 12 h later
anti-CD3/CD28 antibody-coated beads (Invitrogen) were added
for activation.
ELISAs for cytokine concentrations
Activated CD4+ T cells were sedimented 72 h after activation.
The supernatant was harvested to determine concentrations of IL-
1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, and IL-12p70, IFN-c,
TNF-a, and TNF-b using Quantikine Mouse Immunoassay
according to the manufacturer’s protocol (R&D Systems, Minne-
apolis, MN, USA). Data were read out using an LSR II flow
cytometer (BD Biosciences) following the manufacturer’s protocol.
Data were evaluated with Bender Med Systems software (http://
www.bendermedsystems.com/software-flowcytomix-pro—51).
Cell culture of TCCs for P2RX5 analysis by flow cytometry
and sequencing
TCCs were grown at 26105 cells/well in 96-well plates. TCC
characteristics are summarized (Table S3). For sequencing, TCCs
were grown in 48-well plates at 36106 cells/well. Cells were
incubated for 24 h in X-Vivo 15 cell culture medium supple-
mented with or without beads coated with antibodies against CD2,
CD3 and CD28 to stimulate cells according to the manufacturer’s
instructions (MACS T cell activation/expansion kit, Miltenyi).
TCCs were characterized as mentioned elsewhere [23].
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Flow cytometry
Cells were stained for the exclusion of dead cells (LIVE/DEAD
Fixable Dead Cell Stain Kit, Invitrogen). For surface staining cells
were resuspended in blocking buffer (PBS, 10% donkey serum,
10% of 1 mg/ml human IgG (Jackson ImmunoResearch). After
15 min of incubation at 4uC, cells were stained using monoclonal
antibodies against surface markers. Anti-CD3 Pacific Blue (clone
UCHT1), anti-CD3 PE cyanine 7 (clone UCHT1), anti-CD4
allophycocyanin (APC) (clone RPA-T4), and anti-HLA-ABC PE
(clone W6/32) antibodies were purchased from eBioscience (San
Diego, CA, USA), anti-CD8 Pacific Blue (clone DN25) from
Dako, and antibodies anti-CD27 APC Alexa750 (clone CLB-27/
1), CD45RA PE cyanine 5.5 (clone MEM-56) from Invitrogen. In
addition the polyclonal rabbit anti-human P2RX5 antibody
(ProteinTech Group, Chicago, IL, USA) and the polyclonal
rabbit IgG isotype control (Dianova, Hamburg, Germany) were
included. Cells were stained for 30 min at 4uC. For detection of
anti-P2RX5 antibody, cells were stained for 30 min at 4uC in the
presence of donkey anti-rabbit IgG DyLight488 antibody (Jackson
ImmunoResearch). Cells were washed with PBS, fixed and
analyzed by flow cytometry.
For intracellular staining cells were fixed for 20 min at RT by
the addition of Fixation Buffer (eBioscience). Cells were washed in
permeabilization buffer (PBS, 5% FCS, 1 g/l Triton-X-100, 20 g/
l BSA). Subsequently, cells were resuspended in blocking buffer
which contained permeabilization buffer, 10% donkey serum as
well as 10% of 1 mg/ml human IgG. After 15 min of incubation
on ice the anti-CD3 Pacific Blue, anti-CD4 APC, anti-HLA-ABC
PE, anti-P2RX5 antibodies and rabbit IgG isotype control
antibodies were added, respectively. Cells were incubated for
30 min at 4uC and washed twice with permeabilization buffer.
Afterwards anti-rabbit IgG DyLight488 antibody was added and
cells were incubated for 30 min at 4uC. Cells were analyzed using
a LSR II flow cytometer. Data was analyzed by using the FlowJo
software (TreeStar, Ashland, OR, USA).
Sequencing
TCCs were cultured for 24 h, centrifuged (5 min, 350xg), the
cell pellets were resuspended in 350 ml buffer RLT (Qiagen) and
frozen at -80uC. For RNA extraction, the RNeasy mini kit was
used (Qiagen). RNA concentrations were determined by using the
NanoDrop 1000 (Thermo Scientific, Waltham, MA, USA). 1 mg
RNA of each approach was subjected to cDNA synthesis by
following the instructions of the RevertAid H Minus First Strand
cDNA Synthesis Kit (Thermo Scientific). Ten-fold dilutions of
oligo (dT)-primed cDNA were amplified by PCR for 35 cycles of
45 sec at 95uC, 1 min at 60uC and 1.5 min at 72uC. Afterwards
nested PCR was done. Primer sequences were: sense 59-
TCCCCAAATTCAACTTCTCC-39, antisense 59-
TTCTGACTGCTGCTTCCACG-39, sense (nested) 59-
GCAATGTGATGGAC-GTCAAGG-39 and antisense (nested)
59-TGAGCTGCTCAGATAGCCCC-39. The PCR products
were loaded on a 1.5% agarose gel for electrophoresis. Bands of
approximately 516 bp were eluted using the Gel-Extraction Kit
(GE Healthcare, Chalfont St Giles, UK). Finally, PCR products
were used as templates in a second nested PCR, seperated on a
1.5% agarose gel and extracted as described before. The final
PCR product was used for sequencing with a BigDye Terminator
V1.1 cycle sequencing kit (Applied Biosystems) and a 3130 genetic
analyzer (Applied Biosystems/Hitachi).
Supporting Information
Figure S1 Expression of P2RX5 by human T cells is
activation-dependent. A, KCNN4 and P2RX5 mRNA
expression changes were compared in CD4+ and CD8+ T cells
activated with different protocols. Activation protocols are
indicated at the right-hand side. PBMCs were activated with
PHA-L in medium with (+) or without (2) serum (X-Vivo 15,
Lonza), or with anti-CD3 antibodies (DOKA) in serum free
medium. CD4+ and CD8+ T cells were separated after activation
and subjected to mRNA expression analysis by qPCR (see
Materials and Methods). Error bars are SEM, n = 3. n.s. – not
significant; * - significant. Significance was analyzed using two-way
ANOVA test (p,0.0001), Bonferroni-Posthoc test, and Students
T-Test (p,0.05). B, Ion channel mRNA expression changed upon
activation of PBMCs with anti-CD3 antibody. Experimental
conditions were as described above. Error bars are SEM, n = 3. C,
CD25 mRNA expression increased in activated CD4+ T cells in
the course of time. CD4+ T cells were activated with anti-CD3/
CD28 antibody-coated beads. CD25 mRNA expression level (%)
was determined with qPCRs at the times indicated (n = 3, SEM). D
– mRNA expression level after 12 h in the presence of
cycloheximide. For further details see Materials and Methods.
D, P2RX5 protein colocalized with talin in the IS. CD4+ T cells
were incubated with either streptavidin beads for control or anti-
CD3/CD28 antibody-coated streptavidin beads for activation.
Overlay of staining patterns obtained with anti-talin (green) and
anti-P2RX5 antibodies (red), pictures represent overviews of
magnifications shown in Fig. 3. Scale bars – 10 mm. E, Activated
CD4+ T cells transfected with P2RX5 siRNA or control siRNA
produced interleukins. CD4+ T cells transfected with P2RX5-
siRNA or control-siRNA were activated for 72 h with anti-CD3/
CD28-coated beads. Subsequently, interleukin concentration was
assessed in the supernatant by ELISA. F, Knock-down of P2RX5
mRNA decreased the number of activated CD4+ T cells. CD4+ T
cells (56106 cells) were activated with anti-CD3/CD28 antibody-
coated beads for 72 h. Subsequently cells were counted in a
counting chamber. Cell numbers were normalized to those of
untransfected control CD4+ T cells (gray bar; set to 100%). White
and black bar - number of cells transfected with control-siRNA
and P2RX5-siRNA, respectively. Error bars are SEM, n = 3. n.s. –
not significant; * - significant, Students T-test (p,0.005). G,
PBMCs were used for analysis of P2RX5 expression by T cells.
P2RX5+ subsets were identified in flow cytometry experiments in
bulk CD4+ T cell populations, but also in naı¨ve and memory
CD4+ T cell subsets. In brief, after dead cell exclusion gated CD3+
HLA-ABC+ populations were used to further determine
CD4+P2RX5+ T cell frequencies and medFI values. CD4+ T
cells were also used to gate on CD45RA+CD27+ naı¨ve and
CD45RA-CD27+ memory CD4+ T cells for P2RX5 expression
analysis. H, P2RX5 is expressed by a minor frequency of
unstimulated CD4+ and CD8+ T cells of bulk PBMCs.
Furthermore, the data indicate a higher frequency of P2RX5+
naı¨ve T cells compared to P2RX5+ memory T cells. Bars represent
mean values 6SEM (n = 3). Statistical analysis was performed by
paired t-test.
(TIF)
Table S1 List of ion channel subunits probed on custom-made
oligonucleotide array.
(DOCX)
Table S2 Changes in ion channel mRNA expression upon
PBMC stimulation with PHA-L.
(DOCX)
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Table S3 Characteristics of human TCCs used for P2RX5
protein expression analysis and RNA sequencing.
(DOCX)
Acknowledgments
The authors thank S. Scholten and S. Meyer (Dept. of Biology, University
of Hamburg) for invaluable assistance in making the microarray. We are
very grateful to Sara Yousef for providing the T cell clones and to Petra
Breiden for technical sequencing support.
Author Contributions
Conceived and designed the experiments: PA CO RM OP. Performed the
experiments: PA CO. Analyzed the data: PA CO RM OP. Contributed to
the writing of the manuscript: PA CO RM OP.
References
1. Kupfer A, Kupfer H (2003) Imaging immune cell interactions and functions:
SMACs and the Immunological Synapse. Semin Immunol 15: 295–300.
2. Dustin ML (2008) T-cell activation through immunological synapses and
kinapses. Immunol Rev 221: 77–89.
3. Huppa JB, Davis MM (2003) T-cell-antigen recognition and the immunological
synapse. Nat Rev Immunol 3: 973–983.
4. Yeh J-H, Sidhu SS, Chan AC (2008) Regulation of a late phase of T cell polarity
and effector functions by Crtam. Cell 132: 846–859.
5. Huppa JB, Gleimer M, Sumen C, Davis MM (2003) Continuous T cell receptor
signaling required for synapse maintenance and full effector potential. Nat
Immunol 4: 749–755.
6. Ueda H, Morphew MK, McIntosh JR, Davis MM (2011) CD4+ T-cell synapses
involve multiple distinct stages. PNAS 108: 17099–17104.
7. Heissmeyer V, Macia´n F, Im S-H, Varma R, Feske S, et al. (2004) Calcineurin
imposes T cell unresponsiveness through targeted proteolysis of signaling
proteins. Nat Immunol 5: 255–265.
8. Ehrlich LIR, Ebert PJR, Krummel MF, Weiss A, Davis MM (2002) Dynamics of
p56lck translocation to the T cell immunological synapse following agonist and
antagonist stimulation. Immunity 17: 809–822.
9. Beal AM, Anikeeva N, Varma R, Cameron TO, Vasiliver-Shamis G, et al.
(2009) Kinetics of early T cell receptor signaling regulate the pathway of lytic
granule delivery to the secretory domain. Immunity 31: 632–642.
10. Berger SB, Sadighi Akha AA, Miller RA (2005) A glycoprotein endopeptidase
enhances calcium influx and cytokine production by CD4+ T cells of old and
young mice. Int Immunol 17: 983–991.
11. Detre C, Kiss E, Varga Z, Luda´nyi K, Pa´szty K, et al. (2006) Death or survival:
membrane ceramide controls the fate and activation of antigen-specific T-cells
depending on signal strength and duration. Cell Signal 18: 294–306.
12. Keller AM, Groothuis TA, Veraar EAM, Marsman M, Maillette de Buy
Wenniger L, et al. (2007) Costimulatory ligand CD70 is delivered to the
immunological synapse by shared intracellular trafficking with MHC class II
molecules. PNAS 104: 5989–5994.
13. Suzuki K, Okuno T, Yamamoto M, Pasterkamp RJ, Takegahara N, et al. (2007)
Semaphorin 7A initiates T-cell-mediated inflammatory responses through
alpha1beta1 integrin. Nature 446: 680–684.
14. Lewis RS (2001) Calcium signaling mechanisms in T lymphocytes. Annu Rev
Immunol 19: 497–521.
15. Feske S (2007) Calcium signalling in lymphocyte activation and disease. Nat Rev
Immunol 7: 690–702.
16. Cahalan MD, Chandy KG (2009) The functional network of ion channels in T
lymphocytes. Immunol Rev 231: 59–87.
17. Kummerow C, Junker C, Kruse K, Rieger H, Quintana A, et al. (2009) The
immunological synapse controls local and global calcium signals in T
lymphocytes. Immunol Rev 231: 132–147.
18. Lioudyno MI, Kozak JA, Penna A, Safrina O, Zhang SL, et al. (2008) Orai1 and
STIM1 move to the immunological synapse and are up-regulated during T cell
activation. PNAS 105: 2011–2016.
19. Nicolaou SA, Neumeier L, Peng Y, Devor DC, Conforti L (2007) The Ca(2+)-
activated K(+) channel KCa3.1 compartmentalizes in the immunological
synapse of human T lymphocytes. Am J Physiol Cell Physiol 292: C1431–9.
20. North RA (2002) Molecular physiology of P2X receptors. Physiol Rev 82: 1013–
1067.
21. Wenning AS, Neblung K, Strauss B, Wolfs M-J, Sappok A, et al. (2011) TRP
expression pattern and the functional importance of TRPC3 in primary human
T-cells. Biochim Biophys Acta 1813: 412–423.
22. De Rijke B, van Horssen-Zoetbrood A, Beekman JM, Otterud B, Maas F, et al.
(2005) A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T
lymphocyte response associated with remission of chronic myeloid leukemia.
J Clin Invest 115: 3506–3516.
23. Aly L, Yousef S, Schippling S, Jelcic I, Breiden P, et al. (2011) Central role of JC
virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopa-
thy-immune reconstitution inflammatory syndrome. Brain 134: 2687–2702.
24. Duckwitz W, Hausmann R, Aschrafi A, Schmalzing G (2006) P2X5 subunit
assembly requires scaffolding by the second transmembrane domain and a
conserved aspartate. J Biol Chem 281: 39561–39572.
25. Nicke A, Ba¨umert HG, Rettinger J, Eichele A, Lambrecht G, et al. (1998) P2X1
and P2X3 receptors form stable trimers: a novel structural motif of ligand-gated
ion channels. EMBO J 17: 3016–3028.
26. Nicke A, Rettinger J, Schmalzing G (2003) Monomeric and dimeric byproducts
are the principal functional elements of higher order P2X1 concatamers. Mol
Pharmacol 63: 243–252.
27. Aschrafi A, Sadtler S, Niculescu C, Rettinger J, Schmalzing G (2004) Trimeric
architecture of homomeric P2X2 and heteromeric P2X1+2 receptor subtypes.
J Mol Biol 342: 333–343.
28. Barrera NP, Ormond SJ, Henderson RM, Murrell-Lagnado RD, Edwardson
JM (2005) Atomic force microscopy imaging demonstrates that P2X2 receptors
are trimers but that P2X6 receptor subunits do not oligomerize. J Biol Chem
280: 10759–10765.
29. Jiang L-H, Kim M, Spelta V, Bo X, Surprenant A, et al. (2003) Subunit
arrangement in P2X receptors. J Neurosci 23: 8903–8910.
30. Leˆ KT, Paquet M, Nouel D, Babinski K, Se´gue´la P (1997) Primary structure and
expression of a naturally truncated human P2X ATP receptor subunit from
brain and immune system. FEBS Lett 418: 195–199.
31. Banchereau J, Thompson-Snipes L, Zurawski S, Blanck J-P, Cao Y, et al. (2012)
The differential production of cytokines by human Langerhans cells and dermal
CD14(+) DCs controls CTL priming. Blood 119: 5742–5749.
32. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, et al. (2004) Interleukin-10
and related cytokines and receptors. Annu Rev Immunol 22: 929–979.
33. Balasa B, La Cava A, Van Gunst K, Mocnik L, Balakrishna D, et al. (2000) A
mechanism for IL-10-mediated diabetes in the nonobese diabetic (NOD) mouse:
ICAM-1 deficiency blocks accelerated diabetes. J Immunol 165: 7330–7337.
34. Overes IM, de Rijke B, van Horssen-Zoetbrood A, Fredrix H, de Graaf AO, et
al. (2008) Expression of P2X5 in lymphoid malignancies results in LRH-1-
specific cytotoxic T-cell-mediated lysis. Br J Haematol 141: 799–807.
35. Whitmire JK, Flavell RA, Grewal IS, Larsen CP, Pearson TC, et al. (1999)
CD40-CD40 ligand costimulation is required for generating antiviral CD4 T cell
responses but is dispensable for CD8 T cell responses. J Immunol 163: 3194–
3201.
36. Kopf M, Ruedl C, Schmitz N, Gallimore A, Lefrang K, et al. (1999) OX40-
deficient mice are defective in Th cell proliferation but are competent in
generating B cell and CTL Responses after virus infection. Immunity 11: 699–
708.
37. Markovic-Plese S, Cortese I, Wandinger KP, McFarland HF, Martin R (2001)
CD4+CD28- costimulation-independent T cells in multiple sclerosis. J Clin
Invest 108: 1185–1194.
38. Szabo SJ, Sullivan BM, Stemmann C, Satoskar AR, Sleckman BP, et al. (2002)
Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma
production in CD4 and CD8 T cells. Science (80-) 295: 338–342.
39. Ku¨ndig TM, Shahinian a, Kawai K, Mittru¨cker HW, Sebzda E, et al. (1996)
Duration of TCR stimulation determines costimulatory requirement of T cells.
Immunity 5: 41–52.
40. Iezzi G, Karjalainen K, Lanzavecchia A (1998) The duration of antigenic
stimulation determines the fate of naive and effector T cells. Immunity 8: 89–95.
41. Battaglia C, Salani G, Consolandi C, Bernardi LR, De Bellis G (2000) Analysis
of DNA microarrays by non-destructive fluorescent staining using SYBR green
II. Biotechniques 29: 78–81.
42. Diehl F, Beckmann B, Kellner N, Hauser NC, Diehl S, et al. (2002)
Manufacturing DNA microarrays from unpurified PCR products. Nucleic
Acids Res 30: e79.
43. Alizadeh AA, Staudt LM (2000) Genomic-scale gene expression profiling of
normal and malignant immune cells. Curr Opin Immunol 12: 219–225.
44. Huse M, Lillemeier BF, Kuhns MS, Chen DS, Davis MM (2006) T cells use two
directionally distinct pathways for cytokine secretion. Nat Immunol 7: 247–255.
Role of P2RX5 Variant in T Cell Polarity
PLOS ONE | www.plosone.org 9 September 2014 | Volume 9 | Issue 9 | e104692
